Neoantigenic receptor ROR1 promotes cell growth through diverse and complementary mechanisms

Aberrant expression of neoantigenic receptor ROR1 has been identified in diverse lymphomas, including mantle cell lymphoma (MCL) and in a broad spectrum of nonlymphoid malignancies. While ROR1 has emerged as an attractive therapeutic target, its oncogenic role and the underlying mechanisms remain rather poorly characterized. Focusing on MCL, we found that ROR1 expression is heterogeneous and it can be induced under environmental stress. Inhibition of ROR1 expression resulted in cell-cycle suppression and apoptotic cell death. The ROR1 loss affected expression of numerous genes and altered phosphorylation of many proteins, including those involved in cell-cycle progression. ROR1 also promotes the synthesis of pyrimidines and purines, including induction of phosphorylation of enzymes involved in pyrimidine synthesis. Finally, we found that ROR1 induced phosphorylation of DEK and that its depletion abrogates ROR1 expression. These results provide insights into the multi-faceted oncogenic role of ROR1, further justifying targeting ROR1 in MCL and other malignancies.

Authors

Institutions

Publication Details

Journal
Leukemia
Published
2026-10-14
DOI
https://doi.org/10.1038/s41375-026-03169-w
Primary Topic
T-cell and B-cell Immunology
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Neoantigenic receptor ROR1 promotes cell growth through diverse and complementary mechanisms

Nicholas Mackrides, Suzanne Paley, Pradeep Kumar Gupta, Cosimo Lobello et al.
Leukemia
T-cell and B-cell Immunology
article

Neoantigenic receptor ROR1 promotes cell growth through diverse and complementary mechanisms

Nicholas Mackrides, Suzanne Paley, Pradeep Kumar Gupta, Cosimo Lobello, Nashwa Mansoor, Vanessa Dupoux, Reza Nejati, Don A. Baldwin, Mariusz A. Wasik, Phassawan Rungsiprakarn, German Ott, Johnvesly Basappa, Peter D. Karp, Mowafaq Jillab, Shengchun Wang, Shilpa Rao, David Rushmore, Bhaumik Shah, Andrew Kalgren, Katrin Kurz, Kavindra Nath, Dinesh Singh, Ashishkumar Sonani, K. Qi Cai, Brigitte Dade, Neil V. Sen
article en

Abstract

Aberrant expression of neoantigenic receptor ROR1 has been identified in diverse lymphomas, including mantle cell lymphoma (MCL) and in a broad spectrum of nonlymphoid malignancies. While ROR1 has emerged as an attractive therapeutic target, its oncogenic role and the underlying mechanisms remain rather poorly characterized. Focusing on MCL, we found that ROR1 expression is heterogeneous and it can be induced under environmental stress. Inhibition of ROR1 expression resulted in cell-cycle suppression and apoptotic cell death. The ROR1 loss affected expression of numerous genes and altered phosphorylation of many proteins, including those involved in cell-cycle progression. ROR1 also promotes the synthesis of pyrimidines and purines, including induction of phosphorylation of enzymes involved in pyrimidine synthesis. Finally, we found that ROR1 induced phosphorylation of DEK and that its depletion abrogates ROR1 expression. These results provide insights into the multi-faceted oncogenic role of ROR1, further justifying targeting ROR1 in MCL and other malignancies.

Leukemia
Fox Chase Cancer Center (US), SRI International (US), Robert Bosch Hospital (DE), University of Pennsylvania (US)
National Cancer Institute
Good health and well-being
Openalex Percentile: Top 21%
T-cell and B-cell Immunology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.